MX2012000434A - Metodo de sanacion de herida y modulacion de cicatriz. - Google Patents

Metodo de sanacion de herida y modulacion de cicatriz.

Info

Publication number
MX2012000434A
MX2012000434A MX2012000434A MX2012000434A MX2012000434A MX 2012000434 A MX2012000434 A MX 2012000434A MX 2012000434 A MX2012000434 A MX 2012000434A MX 2012000434 A MX2012000434 A MX 2012000434A MX 2012000434 A MX2012000434 A MX 2012000434A
Authority
MX
Mexico
Prior art keywords
wound healing
scar
modulation
corticosteroids
administration
Prior art date
Application number
MX2012000434A
Other languages
English (en)
Spanish (es)
Inventor
Brian C Keller
Original Assignee
Crescendo Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crescendo Therapeutics Llc filed Critical Crescendo Therapeutics Llc
Publication of MX2012000434A publication Critical patent/MX2012000434A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2012000434A 2009-07-09 2010-07-09 Metodo de sanacion de herida y modulacion de cicatriz. MX2012000434A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22440809P 2009-07-09 2009-07-09
US22621609P 2009-07-16 2009-07-16
PCT/US2010/041576 WO2011006100A1 (en) 2009-07-09 2010-07-09 Method of wound healing and scar modulation

Publications (1)

Publication Number Publication Date
MX2012000434A true MX2012000434A (es) 2012-04-11

Family

ID=43427950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000434A MX2012000434A (es) 2009-07-09 2010-07-09 Metodo de sanacion de herida y modulacion de cicatriz.

Country Status (10)

Country Link
US (1) US20110009374A1 (cg-RX-API-DMAC7.html)
EP (1) EP2451280A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012532889A (cg-RX-API-DMAC7.html)
CN (1) CN102480969A (cg-RX-API-DMAC7.html)
AR (1) AR077410A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010271205A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012001098A2 (cg-RX-API-DMAC7.html)
CA (1) CA2767661A1 (cg-RX-API-DMAC7.html)
MX (1) MX2012000434A (cg-RX-API-DMAC7.html)
WO (1) WO2011006100A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100322875A1 (en) 2009-06-18 2010-12-23 Advanced Bio-Technologies, Inc. Silicone scar treatment preparation
US8623040B2 (en) 2009-07-01 2014-01-07 Alcon Research, Ltd. Phacoemulsification hook tip
WO2012012390A1 (en) 2010-07-19 2012-01-26 Marvphyt Development Llc Botanical composition and methods of manufacture and use
US10258505B2 (en) 2010-09-17 2019-04-16 Alcon Research, Ltd. Balanced phacoemulsification tip
ITMI20111050A1 (it) * 2011-06-10 2012-12-11 Sevecom Spa Uso di emulsionanti in associazione con oleine vegetali in un alimento per animali.
CN103648483A (zh) 2011-06-24 2014-03-19 莫茨制药有限及两合公司 包含洋葱提取物和脂质体的组合物
US9364510B2 (en) 2011-07-19 2016-06-14 Marvphyt Development Llc Botanical composition and methods of manufacture and use
LT2736887T (lt) 2011-07-29 2018-02-12 Karyopharm Therapeutics, Inc. Hidrazidą turintys branduolių transporto moduliatoriai ir jų panaudojimas
WO2013040265A1 (en) * 2011-09-13 2013-03-21 Brigham Young University Technology Commercialization Office Compositions for treating bone diseases and broken bones
US9474685B2 (en) 2011-09-28 2016-10-25 Sure-Shot Medical Device Inc. Apparatus for localized dermatological treatment
GB201120724D0 (en) * 2011-12-01 2012-01-11 Gauthier Rene System and method for alleviating the appearance of scars and/or scar tissue
FR2985064B1 (fr) * 2011-12-23 2016-02-26 Oreal Procede pour delivrer un conseil cosmetique
JP6093007B2 (ja) * 2012-04-27 2017-03-08 ダウ コーニング コーポレーションＤｏｗ Ｃｏｒｎｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ 基質に有効成分を送達するためのシリコーン系賦形剤を含有する局所用製剤組成物
HUE040427T2 (hu) 2012-05-09 2019-03-28 Biogen Ma Inc Nukleáris transzportmodulátorok és felhasználásuk
US11458199B2 (en) * 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
US9808654B2 (en) * 2013-02-11 2017-11-07 Jan Marini Skin Research Post procedure skin care gel and methods of use thereof
EP2968278B8 (en) * 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
CN105122261B (zh) * 2013-04-23 2020-04-24 惠普发展公司，有限责任合伙企业 从遭到破坏的系统启动代码中恢复的方法以及计算装置
EP3492455B1 (en) 2013-06-21 2023-05-17 Karyopharm Therapeutics Inc. 1,2,4-triazoles as nuclear transport modulators and use in the treatment of specific forms of cancer
US11432990B2 (en) 2013-08-30 2022-09-06 ISOS Solutions, LLC Textured apparatus with therapeutic material incorporated therein and methods of manufacturing same
US9226890B1 (en) 2013-12-10 2016-01-05 Englewood Lab, Llc Polysilicone base for scar treatment
EP3087495A4 (en) * 2013-12-23 2017-08-23 Intel Corporation Integrated component interconnect
JP7017311B2 (ja) 2014-06-09 2022-02-08 広東科洛克生物医薬集団有限公司 シリコンベースの生体光組成物およびその使用
MA40433A (fr) 2014-07-21 2017-06-14 Sevecom Spa Émulsion en poudre pour aliments pour animaux
EA201790384A1 (ru) 2014-08-15 2017-08-31 Кариофарм Терапевтикс, Инк. Полиморфы селинексора
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
JP7595413B2 (ja) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
EP3576737A4 (en) 2017-02-06 2021-04-21 Case Western Reserve University COMPOSITIONS AND METHODS OF MODULATING THE ACTIVITY OF SHORT CHAIN DEHYDROGENASE
CA3114363A1 (en) * 2018-09-28 2020-04-02 Joel Studin Transpore delivery of steroids and large molecules
EP3883577A4 (en) 2018-11-21 2022-06-15 Case Western Reserve University COMPOSITIONS AND METHODS FOR MODULATION OF SHORT CHAIN DEHYDROGENASE ACTIVITY
US20200397720A1 (en) * 2019-06-23 2020-12-24 Charles Huntington Gallina Method and formulation for treatment of wounds by new tissue regeneration with reduced trauma and scar tissue formation
CN110368498A (zh) * 2019-08-26 2019-10-25 瑞希(重庆)生物科技有限公司 一种促进伤口愈合的制剂及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337076B1 (en) * 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
KR100362924B1 (ko) * 2000-01-11 2002-11-30 주식회사 동구약품 외피용약제 조성물
CN1443062A (zh) * 2000-05-23 2003-09-17 荷兰联合利华有限公司 除臭剂和/或防汗剂组合物
GB0018466D0 (en) * 2000-07-27 2000-09-13 Strakan Pharm Ltd Keloid Treatment
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
US6495596B1 (en) * 2001-03-23 2002-12-17 Biozibe Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2
US6998421B2 (en) * 2001-06-07 2006-02-14 Biozone Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase - 2
JP4450545B2 (ja) * 2001-07-05 2010-04-14 ロート製薬株式会社 エアゾール製剤
JP4549006B2 (ja) * 2002-05-07 2010-09-22 ロート製薬株式会社 ゲル軟膏
GB0216427D0 (en) * 2002-07-16 2002-08-21 Advanced Biotechnologies Inter Wound dressing
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
WO2005123092A1 (en) * 2004-06-17 2005-12-29 Galderma S.A. Composition for the treatment of psoriasis comprising a silicone agent, a corticosteroid and vitamin d or a derivative thereof
KR20080016612A (ko) * 2005-06-10 2008-02-21 갈데르마 소시에떼아노님 약물, 필름형성 실리콘 및 하나 이상의 휘발성 용매를포함하는 국소조성물을 기초로 하는 피부를 통한 약물의조절된 방출
CN103480026A (zh) * 2007-03-08 2014-01-01 莫科治疗有限公司 一种疤痕敷料制剂
US20080317830A1 (en) * 2007-06-25 2008-12-25 Liolabs Llc Compositions and Methods for the Treatment of Wounds and Scar Tissue
DE102009030931A1 (de) * 2009-06-24 2010-12-30 Eberhard-Karls-Universität Tübingen Universitätsklinikum Chirurgisches Wundverschlusselement

Also Published As

Publication number Publication date
EP2451280A1 (en) 2012-05-16
BR112012001098A2 (pt) 2015-09-01
AU2010271205A1 (en) 2012-02-09
CN102480969A (zh) 2012-05-30
CA2767661A1 (en) 2011-01-13
EP2451280A4 (en) 2012-12-26
WO2011006100A1 (en) 2011-01-13
AR077410A1 (es) 2011-08-24
JP2012532889A (ja) 2012-12-20
US20110009374A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
MX2012000434A (es) Metodo de sanacion de herida y modulacion de cicatriz.
WO2011130302A3 (en) Method of treating obesity using antioxidant inflammation modulators
PH12017500864A1 (en) Anti-notch1 antibodies
IN2012DN03883A (cg-RX-API-DMAC7.html)
MX2011007930A (es) Conjugados de insulina cristalina.
CA2871471C (en) Dna-pk inhibitors
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
IN2012DN02081A (cg-RX-API-DMAC7.html)
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
EP3715457A3 (en) Modulation of prekallikrein (pkk) expression
UA105487C2 (uk) Заміщені дигідропіразолони як інгібітори hif-проліл-4-гідроксилази
ZA201304940B (en) Granzyme b inhibitor compositions, methods and uses for promoting wound healing
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
UA118670C2 (uk) Способи та композиції для загоєння ран
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
MX2011009277A (es) Composicion de leucocito activada.
MX339361B (es) Derivados de alternano.
IN2014DN03010A (cg-RX-API-DMAC7.html)
MX2013002539A (es) Sobrenadante condicionado por leucocitos activados y usos para la cicatrizacion de heridas.
WO2011136513A3 (ko) 디히드록시벤조산 유도체를 포함하는 골이식용 또는 골충진용 조성물
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain
WO2011116351A3 (en) Methods and compositions for the treatment of cancer
MX2011007384A (es) Terapias de combinacion para trastornos neoplásticos.
WO2015050686A3 (en) Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ABBVIE INC.

FA Abandonment or withdrawal